Literature DB >> 25132285

Comparison of Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization for the Evaluation of MDM2 Amplification in Adipocytic Tumors.

Stacey K Mardekian1, Charalambos C Solomides1, Jerald Z Gong1, Stephen C Peiper1, Zi-Xuan Wang1, Renu Bajaj1.   

Abstract

BACKGROUND: Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) are characterized cytogenetically by a 12q13-15 amplification involving the mouse double minute 2 (MDM2) oncogene. Fluorescence in situ hybridization (FISH) is used frequently to detect this amplification and aid with the diagnosis of these entities, which is difficult by morphology alone. Recently, bright-field in situ hybridization techniques such as chromogenic in situ hybridization (CISH) have been introduced for the determination of MDM2 amplification status.
METHODS: The present study compared the results of FISH and CISH for detecting MDM2 amplification in 41 cases of adipocytic tumors. Amplification was defined in both techniques as a MDM2/CEN12 ratio of 2 or greater.
RESULTS: Eleven cases showed amplification with both FISH and CISH, and 26 cases showed no amplification with both methods. Two cases had discordant results between CISH and FISH, and two cases were not interpretable by CISH.
CONCLUSION: CISH is advantageous for allowing pathologists to evaluate the histologic and molecular alterations occurring simultaneously in a specimen. Moreover, CISH is found to be more cost- and time-efficient when used with automation, and the signals do not quench over time. CISH technique is a reliable alternative to FISH in the evaluation of adipocytic tumors for MDM2 amplification.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  MDM2 protein; adipose tissue; human gene amplification in situ hybridization chromogenic compounds; neoplasms

Mesh:

Substances:

Year:  2014        PMID: 25132285      PMCID: PMC6806684          DOI: 10.1002/jcla.21794

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  11 in total

Review 1.  MDM2 oncogene as a novel target for human cancer therapy.

Authors:  H Wang
Journal:  Curr Pharm Des       Date:  2000-03       Impact factor: 3.116

2.  Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.

Authors:  Wenjun Zhang; Abigail McElhinny; Alma Nielsen; Maria Wang; Melanie Miller; Shalini Singh; Ruediger Rueger; Brian P Rubin; Zhen Wang; Raymond R Tubbs; Raymond B Nagle; Pat Roche; Ping Wu; Lidija Pestic-Dragovich
Journal:  Appl Immunohistochem Mol Morphol       Date:  2011-01

3.  Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.

Authors:  Ronald S A de Vreeze; Daphne de Jong; Petra M Nederlof; Aafke Ariaens; Ivon H G Tielen; Luc Frenken; Rick L Haas; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

Review 4.  Small-molecule inhibitors of MDM2 as new anticancer therapeutics.

Authors:  Michael P Dickens; Ross Fitzgerald; Peter M Fischer
Journal:  Semin Cancer Biol       Date:  2009-11-06       Impact factor: 15.707

Review 5.  Well-differentiated and dedifferentiated liposarcomas.

Authors:  Jean-Michel Coindre; Florence Pédeutour; Alain Aurias
Journal:  Virchows Arch       Date:  2009-08-18       Impact factor: 4.064

Review 6.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

Review 7.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

8.  Liposarcoma: molecular genetics and therapeutics.

Authors:  Rachel Conyers; Sophie Young; David M Thomas
Journal:  Sarcoma       Date:  2010-12-27

Review 9.  Contributions of cytogenetics and molecular cytogenetics to the diagnosis of adipocytic tumors.

Authors:  Jun Nishio
Journal:  J Biomed Biotechnol       Date:  2011-01-11

10.  Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH).

Authors:  Hiroaki Nitta; Beatrice Hauss-Wegrzyniak; Megan Lehrkamp; Adrian E Murillo; Fabien Gaire; Michael Farrell; Eric Walk; Frederique Penault-Llorca; Masafumi Kurosumi; Manfred Dietel; Lin Wang; Margaret Loftus; James Pettay; Raymond R Tubbs; Thomas M Grogan
Journal:  Diagn Pathol       Date:  2008-10-22       Impact factor: 2.644

View more
  3 in total

1.  Rare MDM2 amplification in a fat-predominant angiomyolipoma.

Authors:  Maria Del Carmen Rodriguez Pena; Jennifer Gordetsky; Patricia T Greipp; Shi Wei; Guido Martignoni; George J Netto; Shuko Harada; Carlos N Prieto Granada
Journal:  Virchows Arch       Date:  2020-05-15       Impact factor: 4.064

2.  Benzene and its metabolite decreases cell proliferation via LncRNA-OBFC2A-mediated anti-proliferation effect involving NOTCH1 and KLF15.

Authors:  Pengling Sun; Jing Wang; Xiaoli Guo; Yujiao Chen; Caihong Xing; Ai Gao
Journal:  Oncotarget       Date:  2017-06-20

3.  Comparison of Different In Situ Hybridization Techniques for the Detection of Various RNA and DNA Viruses.

Authors:  Vanessa M Pfankuche; Kerstin Hahn; Rogier Bodewes; Florian Hansmann; André Habierski; Ann-Kathrin Haverkamp; Stephanie Pfaender; Stephanie Walter; Christine Baechlein; Alexander Postel; Eike Steinmann; Paul Becher; Albert Osterhaus; Wolfgang Baumgärtner; Christina Puff
Journal:  Viruses       Date:  2018-07-20       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.